Escitalopram co-prescription in anastrozole-treated breast cancer patients

Ozyurt H., Ozden S., Gemici C., Kucukibrahimoglu E., Odabas H., NEŞETOĞLU N., ...More

NORTHERN CLINICS OF ISTANBUL, vol.9, no.3, pp.248-255, 2021 (ESCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 9 Issue: 3
  • Publication Date: 2021
  • Doi Number: 10.14744/nci.2022.48264
  • Journal Name: NORTHERN CLINICS OF ISTANBUL
  • Journal Indexes: Emerging Sources Citation Index (ESCI), Central & Eastern European Academic Source (CEEAS), Directory of Open Access Journals, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.248-255
  • Keywords: Anastrozole, breast cancer, escitalopram, obesity, therapeutic drug monitoring, BODY-MASS INDEX, AROMATASE INHIBITORS, POSTMENOPAUSAL WOMEN, IN-VITRO, DEPRESSION, PHARMACOKINETICS, TAMOXIFEN, OBESITY, METABOLISM, IMPACT
  • Istanbul University Affiliated: Yes

Abstract

OBJECTIVE: The purpose of the study was to evaluate the impact of escitalopram co-prescription on plasma anastrozole levels in post-menopausal breast cancer patients.